Ensysce Biosciences Net Worth

Ensysce Biosciences Net Worth Breakdown

  ENSC
The net worth of Ensysce Biosciences is the difference between its total assets and liabilities. Ensysce Biosciences' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Ensysce Biosciences' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Ensysce Biosciences' net worth can be used as a measure of its financial health and stability which can help investors to decide if Ensysce Biosciences is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Ensysce Biosciences stock.

Ensysce Biosciences Net Worth Analysis

Ensysce Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Ensysce Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Ensysce Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Ensysce Biosciences' net worth analysis. One common approach is to calculate Ensysce Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Ensysce Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Ensysce Biosciences' net worth. This approach calculates the present value of Ensysce Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Ensysce Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Ensysce Biosciences' net worth. This involves comparing Ensysce Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Ensysce Biosciences' net worth relative to its peers.
To determine if Ensysce Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ensysce Biosciences' net worth research are outlined below:
Ensysce Biosciences generated a negative expected return over the last 90 days
Ensysce Biosciences has high historical volatility and very poor performance
Ensysce Biosciences has a very high chance of going through financial distress in the upcoming years
Ensysce Biosciences currently holds 854.7 K in liabilities with Debt to Equity (D/E) ratio of 6.91, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Ensysce Biosciences has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Ensysce Biosciences' use of debt, we should always consider it together with its cash and equity.
The entity reported the previous year's revenue of 2.23 M. Net Loss for the year was (10.63 M) with loss before overhead, payroll, taxes, and interest of (1.23 M).
Ensysce Biosciences currently holds about 3.15 M in cash with (10.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1.
Ensysce Biosciences has a frail financial position based on the latest SEC disclosures
Latest headline from finance.yahoo.com: When Can We Expect A Profit From Ensysce Biosciences, Inc.
Ensysce Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ensysce Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ensysce Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
4th of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Ensysce Biosciences Target Price Consensus

Ensysce target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Ensysce Biosciences' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
   One  Buy
Most Ensysce analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Ensysce stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Ensysce Biosciences, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Ensysce Biosciences Target Price Projection

Ensysce Biosciences' current and average target prices are 5.34 and 13.72, respectively. The current price of Ensysce Biosciences is the price at which Ensysce Biosciences is currently trading. On the other hand, Ensysce Biosciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Ensysce Biosciences Market Quote on 27th of February 2025

Low Price5.34Odds
High Price5.34Odds

5.34

Target Price

Analyst Consensus On Ensysce Biosciences Target Price

Low Estimate12.49Odds
High Estimate15.23Odds

13.72

Historical Lowest Forecast  12.49 Target Price  13.72 Highest Forecast  15.23
Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Ensysce Biosciences and the information provided on this page.

Know Ensysce Biosciences' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Ensysce Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ensysce Biosciences backward and forwards among themselves. Ensysce Biosciences' institutional investor refers to the entity that pools money to purchase Ensysce Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Main Street Group Ltd2024-09-30
0.0
Renaissance Technologies Corp2024-12-31
0.0
Vanguard Group Inc2024-12-31
0.0
Geode Capital Management, Llc2024-12-31
0.0
Anson Funds Management Lp2024-12-31
0.0
Virtu Financial Llc2024-09-30
0.0
Xtx Topco Ltd2024-09-30
0.0
Hrt Financial Llc2024-12-31
0.0
Sabby Management Llc2024-09-30
1.2 M
Perceptive Advisors Llc2024-12-31
86.7 K
Adage Capital Partners Gp Llc2024-12-31
50 K
Note, although Ensysce Biosciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Ensysce Biosciences' market capitalization trends

The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.03 M.

Market Cap

2.35 Billion

Project Ensysce Biosciences' profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(4.51)(4.28)
Return On Capital Employed 15.44  14.67 
Return On Assets(4.51)(4.28)
Return On Equity 29.59  31.06 
The company has Profit Margin (PM) of (1.79) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.19 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.19.
When accessing Ensysce Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Ensysce Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ensysce Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Ensysce Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ensysce Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ensysce Biosciences' management manipulating its earnings.

Evaluate Ensysce Biosciences' management efficiency

Ensysce Biosciences has return on total asset (ROA) of (0.6258) % which means that it has lost $0.6258 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.049) %, meaning that it created substantial loss on money invested by shareholders. Ensysce Biosciences' management efficiency ratios could be used to measure how well Ensysce Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 31.06, whereas Return On Tangible Assets are projected to grow to (4.28). At present, Ensysce Biosciences' Other Current Assets are projected to increase significantly based on the last few years of reporting.
Last ReportedProjected for Next Year
Book Value Per Share(0.33)(0.31)
Tangible Book Value Per Share(0.33)(0.31)
Enterprise Value Over EBITDA(3.00)(3.15)
Price Book Value Ratio(128.22)(134.64)
Enterprise Value Multiple(3.00)(3.15)
Price Fair Value(128.22)(134.64)
Enterprise Value2.7 B2.4 B
Leadership at Ensysce Biosciences emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Revenue
4.4 M
Quarterly Revenue Growth
6.853
Revenue Per Share
10.216
Return On Equity
(2.05)
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ensysce Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ensysce Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ensysce Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Gower Bob G over three weeks ago
Acquisition by Gower Bob G of 7919026 shares of Ensysce Biosciences subject to Rule 16b-3
 
Wright Richard Chester over a month ago
Acquisition by Wright Richard Chester of 49975 shares of Ensysce Biosciences subject to Rule 16b-3
 
Martin Steven Robert over two months ago
Acquisition by Martin Steven Robert of 15000 shares of Ensysce Biosciences subject to Rule 16b-3
 
Silvers Daniel B. over two months ago
Disposition of 359869 shares by Silvers Daniel B. of Ensysce Biosciences subject to Rule 16b-3
 
Weil A Lorne over three months ago
Acquisition by Weil A Lorne of 730110 shares of Ensysce Biosciences at 11.5 subject to Rule 16b-3
 
Carrera Eric over three months ago
Acquisition by Carrera Eric of 30000 shares of Ensysce Biosciences at 11.5 subject to Rule 16b-3
 
Gower Bob G over six months ago
Acquisition by Gower Bob G of 270000 shares of Ensysce Biosciences at 0.4777 subject to Rule 16b-3
 
Birkett Kevin Geoffrey over six months ago
Acquisition by Birkett Kevin Geoffrey of 329250 shares of Ensysce Biosciences at 2.59 subject to Rule 16b-3
 
Weinstein David L. over six months ago
Disposition of tradable shares by Weinstein David L. of Ensysce Biosciences subject to Rule 16b-3
 
Gower Bob G over six months ago
Acquisition by Gower Bob G of 15000 shares of Ensysce Biosciences subject to Rule 16b-3
 
Birkett Kevin Geoffrey over six months ago
Acquisition by Birkett Kevin Geoffrey of 329250 shares of Ensysce Biosciences at 2.59 subject to Rule 16b-3
 
Chang William H over six months ago
Insider Trading

Ensysce Biosciences Corporate Filings

14th of February 2025
Other Reports
ViewVerify
8K
4th of February 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
19th of November 2024
Other Reports
ViewVerify
13A
14th of November 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
Ensysce Biosciences time-series forecasting models is one of many Ensysce Biosciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ensysce Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Ensysce Biosciences Earnings Estimation Breakdown

The calculation of Ensysce Biosciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Ensysce Biosciences is estimated to be -3.1125 with the future projection ranging from a low of -3.1125 to a high of -3.1125. Please be aware that this consensus of annual earnings estimates for Ensysce Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
0.07
-3.11
Lowest
Expected EPS
-3.1125
-3.11
Highest

Ensysce Biosciences Earnings Projection Consensus

Suppose the current estimates of Ensysce Biosciences' value are higher than the current market price of the Ensysce Biosciences stock. In this case, investors may conclude that Ensysce Biosciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Ensysce Biosciences' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of December 2024Current EPS (TTM)
021.2%
0.07
-3.1125
-31.5

Ensysce Biosciences Earnings per Share Projection vs Actual

Actual Earning per Share of Ensysce Biosciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Ensysce Biosciences predict the company's earnings will be in the future. The higher the earnings per share of Ensysce Biosciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.
JavaScript chart by amCharts 3.21.15MarSepSepMar-30-20-10010
JavaScript chart by amCharts 3.21.15Highest Estimate Lowest Estimate Estimated EPS Actual EPS

Ensysce Biosciences Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Ensysce Biosciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Ensysce Biosciences should always be considered in relation to other companies to make a more educated investment decision.
JavaScript chart by amCharts 3.21.15MarSepSepMar-30-25-20-15-10-505
JavaScript chart by amCharts 3.21.15Actual Estimated

Ensysce Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Ensysce Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-11-07
2024-09-30-0.290.070.36124 
2024-08-08
2024-06-30-0.39-0.220.1743 
2024-05-13
2024-03-31-0.9-0.550.3538 
2024-03-15
2023-12-31-0.87-1.37-0.557 
2023-11-09
2023-09-30-1.06-0.870.1917 
2023-08-11
2023-06-30-2.73-0.981.7564 
2023-05-15
2023-03-31-5.08-2.083.059 
2023-03-30
2022-12-31-28.88-18.2410.6436 
2022-11-14
2022-09-30-3.2-0.742.4676 
2022-08-11
2022-06-30-3.4-4.8-1.441 
2022-05-12
2022-03-31-3.2-1.22.062 
2022-03-31
2021-12-31-0.4-9.0-8.62150 
2021-11-15
2021-09-30-0.71-0.710.0

Ensysce Biosciences Corporate Management

When determining whether Ensysce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ensysce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ensysce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ensysce Biosciences Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(31.50)
Revenue Per Share
10.216
Quarterly Revenue Growth
6.853
Return On Assets
(0.63)
Return On Equity
(2.05)
The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.